Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide

Autor: Rik J. Scheper, Sue Ellen Verbrugge, Yehuda G. Assaraf, Huib Ovaa, Gerrit Jansen, Robert H. Shoemaker, Godefridus J. Peters, Rob H. Meloen, Ruud Oerlemans, Celia R. Berkers, George L. Scheffer, Jacqueline Cloos, Jerry W. Slootstra, Ben A. C. Dijkmans

Publikováno v: Investigational New Drugs
Oerlemans, R, Berkers, C R, Assaraf, Y G, Scheffer, G L, Peters, G J, Verbrugge, S E, Cloos, J, Slootstra, J, Meloen, R H, Shoemaker, R H, Dijkmans, B A C, Scheper, R J, Ovaa, H & Jansen, G 2018, ' Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide ', Investigational New Drugs, vol. 36, no. 5, pp. 797-809 . https://doi.org/10.1007/s10637-018-0569-x
Investigational New Drugs, 36(5), 797-809. Kluwer Academic Publishers
Investigational New Drugs, 36(5), 797-809

Summary Background The hexapeptide 4A6 (Ac-Thr(tBu)-His(Bzl)-Thr(Bzl)-Nle-Glu(OtBu)-Gly-Bza) was isolated from a peptide library constructed to identify peptide-based transport inhibitors of multidrug resistance (MDR) efflux pumps including P-glycopr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51de26c79f798655a697b79404426de5
http://www.scopus.com/inward/record.url?scp=85041905364&partnerID=8YFLogxK

Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project

Autor: Dirkjan van Schaardenburg, Maaike Heslinga, Alexandre E. Voskuyl, Rob Schotsman, Ed N. Griep, Willem F. Lems, Inge A. M. van den Oever, Micheal T. Nurmohamed, Yvo M. Smulders, Ben A. C. Dijkmans, Mike J L Peters, H. Griep-Wentink, Maarten Boers, Walter Cambach

Publikováno v: van den Oever, I A M, Heslinga, M, Griep, E N, Griep-Wentink, H R M, Schotsman, R, Cambach, W, Dijkmans, B A C, Smulders, Y M, Lems, W F, Boers, M, Voskuyl, A E, Peters, M J L, van Schaardenburg, D & Nurmohamed, M T 2017, ' Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project ', Rheumatology, vol. 56, no. 9, pp. 1472-1478 . https://doi.org/10.1093/rheumatology/kew497
Rheumatology, 56(9), 1472-1478. Oxford University Press
Rheumatology (Oxford, England), 56(9), 1472-1478. Oxford University Press

Objective To assess the 10-year cardiovascular (CV) risk score and to identify treatment and undertreatment of CV risk factors in patients with established RA. Methods Demographics, CV risk factors and prevalence of cardiovascular disease (CVD) were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52e47a24060d9c627707aa4b98c0ad05
https://research.vumc.nl/en/publications/c63f2254-3396-4057-a474-35894bbe32d8

What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function

Autor: Irene E. van der Horst-Bruinsma, Ben A. C. Dijkmans, Michael T. Nurmohamed, Martijn Steultjens, Salima van Weely, J Christiaan van Denderen, Joost Dekker

Publikováno v: Rheumatology, 52(10):ket240, 1884-1889. Oxford University Press
Van Weely, S F E, Van Denderen, J C, Steultjens, M P M, Nurmohamed, M T, Dijkmans, B A C, Dekker, J & Van der Horst-Bruinsma, I E 2013, ' What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function ', Rheumatology, vol. 52, no. 10, ket240, pp. 1884-1889 . https://doi.org/10.1093/rheumatology/ket240

Objective: A prospective study was conducted in order to establish whether AS patients, who are defined as non-responders after 3 months of anti-TNF therapy, show improvement on performance-based tests of physical functioning. Methods: At baseline an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a724b0600bc015cd7997aa87b4ca27ec
https://doi.org/10.1093/rheumatology/ket240

One-year effects of glucocorticoids on bone density:a meta-analysis in cohorts on high and low-dose therapy

Autor: Merel M E Baak, Mariette C. Lodder, W.F. Lems, Lilian H D van Tuyl, Maarten Boers, Ben A C Dijkmans

Publikováno v: Lems, W F, Baak, M M E, van Tuyl, L H D, Lodder, M C, Dijkmans, B A C & Boers, M 2016, ' One-year effects of glucocorticoids on bone density : a meta-analysis in cohorts on high and low-dose therapy ', RMD Open, vol. 2, no. 2, pp. e000313 . https://doi.org/10.1136/rmdopen-2016-000313
RMD Open
RMD Open, 2(2). BMJ Publishing Group

BACKGROUND: Bone loss during glucocorticoid (GC) therapy is poorly quantified.OBJECTIVE: Quantification of bone loss in GC-treated patients with chronic inflammatory diseases (CID; low dose) and transplants (high dose).METHODS: Meta-analysis of cohor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43ec964ae08157c49cde7ad78fa903ab
https://research.vumc.nl/en/publications/20d82add-f7c9-4a92-9221-0552c3c5675f

Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: Balance between diabetogenic effects and inflammation reduction

Autor: Ben A. C. Dijkmans, Johannes W. J. Bijlsma, Michaela Diamant, Willem F. Lems, Michael T. Nurmohamed, Jos N. Hoes, Daniël H. van Raalte, Debby den Uyl

Publikováno v: Arthritis & Rheumatism. 64:639-646

Objective To investigate the dose-related effects of glucocorticoid treatment on glucose tolerance, beta cell function, and insulin sensitivity in patients with early active rheumatoid arthritis (RA). Methods A randomized, controlled, single-blind tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3313af5bd63da195f27121a851a4f13d
https://doi.org/10.1002/art.33378